Nevertheless, similar to studies that have evaluated the use of combination therapies with PD-1 and EGFR inhibitors in recurrent or metastatic HNSCC, the use of tislelizumab plus nimotuzumab demonstrated satisfactory response rates and OS in patients with a ECOG PS score ≥ 2 who have recurrent or metastatic OSCC. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.